Skip to content
Aussie8 – Lifestyle
Author:
iBio, Inc.
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
June 2, 2026
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
May 13, 2026
iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
May 11, 2026
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
April 8, 2026
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
March 28, 2026
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
March 17, 2026
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
March 9, 2026